Get notified of page updates
Public Policy Priorities
Review some of FORCE's current legislative and regulatory policy priorities that impact the hereditary cancer community.

Stay up to date on research and information

Sign Up for FORCE Newsletters

Policy Archive

EARLY Act Brings Young Breast Cancer to Forefront

Hereditary Cancer Awareness

The Breast Cancer Education and Awareness Requires Learning Young Act of 2009 (EARLY Act), HR 1740, was introduced by Representative Wasserman Schultz (D-FL), a breast cancer survivor who carries a BRCA2 mutation. FORCE participated in a coalition of groups providing guidance on the proposed legislation.

EARLY Act logoPassed as part of the Patient Protection and Affordable Care Act in March 2010, the EARLY Act authorized a nationwide awareness and support campaign for women age 45 and under, including high-risk women, breast cancer survivors, and their doctors. The law also includes broad-reaching public and healthcare professional education campaigns, prevention research, and additional support for young women diagnosed with breast cancer. Initially funded for five years, the EARLY Act Reauthorization of 2014 was passed on December 28, 2014. 

Since that time, the initiative has brought about a number of programs including the CDC's Bring Your Brave Campaign and Program Support for Survivor Organizations—including the FORCE XRAY Program, among other activities.

Take Action Now Become an Advocate 2024 Priorities Federal Policy State Policy Advocacy Archive

News Briefs

4/3/2024 - Submitted comments to Senator Cassidy and the HELP Committee in response to an RFI regarding oversight of clinical diagnostic tests, known as in vitro diagnostics (IVDs) and laboratory-developed tests (LDTs).

3/15/2024 - Joined the Coalition to Increase Access to Cancer Care (CIACC) in comments to House leadership on efforts to strengthen the Employee Retirement Income Security Act (ERISA) and emphasize the need to pass the Cancer Drug Parity Act.

3/1/2024 - Provided feedback to CMS on the Medicare Advantage Advanced Notice and accompanying Part D Redesign Program provisions aimed at reducing and managing beneficiary out-of-pocket costs in the Medicare Part D program.

2/29/2024 - Wrote sponsors to endorse the BENEFIT Act, which would require the FDA to include in the benefit-risk assessment framework of a new drug application how patient experience data was considered in the review process.

More